Invention Grant
- Patent Title: Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1
-
Application No.: US15112854Application Date: 2015-01-27
-
Publication No.: US09987351B2Publication Date: 2018-06-05
- Inventor: Deborah Revaud , Cecile Bauche
- Applicant: THERAVECTYS
- Applicant Address: FR Paris
- Assignee: THERAVECTYS
- Current Assignee: THERAVECTYS
- Current Assignee Address: FR Paris
- Agency: Whitham, Curtis & Cook, P.C.
- Priority: EP14290009 20140127
- International Application: PCT/IB2015/050598 WO 20150127
- International Announcement: WO2015/111024 WO 20150730
- Main IPC: A61K39/21
- IPC: A61K39/21 ; A61K39/12 ; C07K14/05 ; C07K14/15 ; C07K14/005 ; C12N7/00 ; C12N15/86 ; A61K39/00

Abstract:
The present invention relates to compositions, methods, and uses employing lentiviral vector particles for induction of an immune response by administration to a human, wherein the lentiviral vector particles comprise a lentiviral vector, wherein the DNA of the lentiviral vector comprises a promoter directing expression of a HTLV-1 p12p30-Tax-HBZ fusion protein. The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.
Public/Granted literature
- US20160331831A1 LENTIVIRAL VECTORS FOR GENERATING IMMUNE RESPONSES AGAINST HUMAN T LYMPHOTROPHIC VIRUS TYPE 1 Public/Granted day:2016-11-17
Information query